CAMLINFINE Camlin Fine Q4 FY25 results (Jan–Mar 2025) and concall
Camlin Fine Sciences delivered a resilient Q4 and FY25 performance, with core business revenue growing 15% YoY and EBITDA improving by 12.5%. The Blends segment showed strong growth, and the Aroma business, particularly vanillin, is poised for significant gains due to anti-dumping duties. The company successfully reduced its net debt and outlined a clear strategy for minimizing losses from discontinued operations, aiming for full vanillin capacity utilization within two years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 417 | 431 | 432 |
| EBITDA | 52 | 56 | 62 |
| Net profit | -116 | -7 | 0 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
